161.04 % to Target, H.C. Wainwright Reiterates ‘Buy’ Rating on EDAP TMS (NASDAQ:EDAP) Shares Today

May 16, 2018 - By Dolores Ford


EDAP TMS (NASDAQ:EDAP) Rating Reaffirmed

In a report revealed to clients and investors on Wednesday, 16 May, The Buy rating of EDAP TMS (NASDAQ:EDAP) shares was restate at H.C. Wainwright, who now has a $6.5000 PT on the stock. H.C. Wainwright’s PT would suggest a possible upside of 161.04 % from the last price of the company.

The stock increased 2.47% or $0.06 during the last trading session, reaching $2.49. About 34,545 shares traded. EDAP TMS S.A. (NASDAQ:EDAP) has declined 8.41% since May 17, 2017 and is downtrending. It has underperformed by 19.96% the S&P500.

EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company has market cap of $72.21 million. The firm operates in two divisions: High Intensity Focused Ultrasound , and Urology Devices and Services (UDS). It currently has negative earnings. The HIFU division develops, makes, and markets devices for the minimally invasive destruction of various types of localized tumors using HIFU technology.

More recent EDAP TMS S.A. (NASDAQ:EDAP) news were published by: Nasdaq.com which released: “EDAP TMS SA : EDAP TMS SA to Announce First Quarter 2018 Financial Results on Monday, May 14” on May 02, 2018. Also Seekingalpha.com published the news titled: “EDAP’s (EDAP) CEO Marc Oczachowski on Q1 2018 Results – Earnings Call Transcript” on May 15, 2018. Nasdaq.com‘s news article titled: “EDAP TMS SA : EDAP Reports 2018 First Quarter Results” with publication date: May 14, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.